LISCure Biosciences, a South Korea-based clinical-stage biopharmaceutical company, announced on Friday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for LB-P8, its investigational drug for the treatment of primary sclerosing cholangitis (PSC).
PSC is a rare, chronic, cholestatic liver disease with significant unmet medical needs as there are no approved drugs available to treat it.
LB-P8 is undergoing assessment in a Phase 2 study in patients with PSC. According to LISCure, it is the only live biotherapeutic product currently reported to be in clinical development to address the requirement of individuals with PSC.
The company is carrying out a Phase 2 study in multiple sites across the US and Europe. Preliminary results are expected to be revealed in early 2025. Based on the results, the company says that it will make maximum use of accelerated programmes to bring LB-P8 to market as quickly as possible.
LB-P8 is also being developed for metabolic dysfunction-associated steatohepatitis (MASH).
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration